抗生素
体内
微生物学
金黄色葡萄球菌
抗菌活性
细菌
体外
生物
抗菌剂
抗生素耐药性
革兰氏阳性菌
万古霉素
生物化学
生物技术
遗传学
作者
Girish Mahajan,Becky Thomas,Rajashri Parab,Zarine E. Patel,Sandip Kuldharan,Vijayaphanikumar Yemparala,K. Narayan Prabhu,Prafull Ranadive,Lisette D’Souza,Koteppa Pari,H Sivaramkrishnan
摘要
ABSTRACT Drug resistance has become a global threat that, if not addressed, may return us to the preantibiotic era. A way to overcome the problem of growing incidence of global antibiotic resistance is to introduce compounds belonging to classes that are new to the clinic. During a screening of the marine microbial extract library for new antibiotics, one of the extracts showed promising antibacterial activity against Gram-positive organisms. Bioactivity-guided isolation and characterization of active metabolites led to the discovery of a novel thiazolyl cyclic-peptide antibiotic, PM181104. It was isolated and characterized from a marine sponge-associated actinobacterium strain of the genus Kocuria (MTCC 5269). The compound exhibited a potent in vitro antibacterial activity against a broad range of Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE). The MIC values evaluated for the compound were found to be in the single-digit nanomolar range. In in vivo studies of PM181104 in a BALB/c murine septicemia model, the compound displayed 100% effective dose (ED 100 ) values of 2.5 and 5.0 mg/kg of body weight against MRSA and 10.0 mg/kg against VRE. In this report, in vitro and in vivo studies of PM181104 are described.
科研通智能强力驱动
Strongly Powered by AbleSci AI